We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/ hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6weeks of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral prefrontal cortex, parietal cortex and cerebellum but not dorsal anterior midcingulate cortex (daMCC). These results suggest that ATMX and MPH have similar but not identical brain effects.
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Introduction
Attention-deficit/hyperactivity disorder is among the most common neurobehavioral disorders in children and adolescents, and frequently persists into adulthood. Atomoxetine (ATMX), a nonstimulant norepinephrine transporter (NET) specific reuptake inhibitor, is a safe and effective treatment for ADHD (Adler et al., 2005) . While a few studies have provided insights (Arnsten, 2006; Seneca et al., 2006; Logan et al., 2007; Pliszka, 2007; Chamberlain et al., 2009; Takano et al., 2009 ), the neural mechanisms by which ATMX exerts therapeutic effects remain unresolved.
Convergent data implicate dysfunction of many brain regions in ADHD pathophysiology, including the dorsal anterior midcingulate (daMCC), dorsolateral prefrontal (DLPFC), and parietal cortices (together, the cingulo-frontal-parietal [CFP] cognitive-attention network), along with the striatum and cerebellum (Paloyelis et al., 2007; Bush, 2009 Bush, , 2011 . Thus, it was expected that ATMX treatment would affect the CFP network. We used the Multi-Source Interference Task (MSIT), cognitive functional magnetic resonance imaging (fMRI) paradigm with demonstrated ability to activate daMCC and the CFP network (Bush and Shin, 2006) . Since clinical response may not maximally differentiate from placebo until 6 weeks with ATMX (Montoya et al., 2009) or methylphenidate (MPH) (Spencer et al., 2005; Biederman et al., 2006) , we scanned subjects at baseline and after 6 weeks of treatment.
Specifically, we hypothesized ATMX would increase fMRI activation in CFP regions that subserve attention and cognition. We also predicted that compared to our previously published sample of 21 adults with ADHD-childhood onset (ADHD-CO) (Bush et al., 2008) , ATMX fMRI responses would be similar to those produced by MPH and differentiable from placebo. To facilitate cross-study comparability and explore the degree of neurobiological overlap of ADHD not otherwise specified (ADHD-NOS) with we compared baseline MSIT fMRI data of the 11 adults with ADHD-NOS with those from the previously published sample.
Methods
Methods were identical to those used in the previously published sample (Bush et al., 2008) 
